ReachMD Faculty
Public Profile
Donna Jarmusz, MA
-
There are no peers to display.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
advertisement
Recommended
CME/CE
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
0.25 credits
<p>IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy</p>
CME/CE
Updates From the 7th World Symposium Task Force
1.00 credits
<p><span data-contrast="auto" xml:lang="EN-US">Updates From the 7th World Symposium Task Force</span><span data-ccp-props='{"201341983":0,"335559738":210,"335559739":210,"335559740":240}'> </span></p>
CME/CE
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies
1.00 credits
<p>Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies</p>
CME/CE
TIME OUT: A Case-Based Deep Dive into the Challenges of ARIA Management
0.50 credits
<p>TIME OUT: A Case-Based Deep Dive into the Challenges of ARIA Management</p>
CME/CE
New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure
0.50 credits
<p>New Horizons: Unraveling Novel Therapies for Enhanced Cardiovascular Outcomes in Patients With Heart Failure</p>
MinuteCE®
A Practical Guide to Prescribing in HF
0.75 credits
<p>A Practical Guide to Prescribing in HF</p>
MinuteCE®
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
0.75 credits
<p><span data-contrast="auto" style="list-style-type: disc;" xml:lang="EN-US">Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies</span></p>
MinuteCE®
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
0.75 credits
<p><span data-contrast="none" style="list-style-type: disc;" xml:lang="EN-US">The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC</span></p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?